HEMATOLOGÍA

CALBACHO, María

  • Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. Int J Infect Dis. 2023 Oct 18;137:98-110 [doi]
  • COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021 Oct;35(10):2885-2894 [doi]
  • COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA). Haematologica. 2023 Jan 1;108(1):22-33 [doi]
  • COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022 Mar 10;139(10):1588-92 [doi]
  • COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021 Oct 14;14(1):168 [doi]
  • Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024 Mar 18;71:102553 [doi]
  • Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023 Jun 13;7(11):2645-2655 [doi]
  • Molnupiravir compared to Nirmatrelvir/Ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA Registry. Int J Antimicrob Agents. 2023 Oct;62(4):106952 [doi]
  • The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2024 Feb;65(2):199-208 [doi]
  • Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21 [doi]

CARREÑO GÓMEZ-TARRAGONA, Gonzalo

  • Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 Feb 4;11(2):21 [doi]
  • Breakthrough infections in MPN-COVID vaccinated patients. Blood Cancer J. 2022 Nov 15;12(11):154 [doi]
  • Determinants of early triage for hospitalization in MPN patients with COVID-19. Am J Hematol. 2022 Sep 16 [doi]
  • High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 Feb;35(2):485-493 [doi]
  • Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 Jun 16;11(6):115 [doi]
  • Second versus first wave of COVID-19 in patients with MPN. Leukemia. 2022 Mar;36(3):897-900 [doi]

CARREÑO GÓMEZ-TARRAGONA, Gonzalo; Santiago BARRIO GARCÍA y Joaquín MARTÍNEZ LÓPEZ

  • A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. Res Sq [Preprint]. 2020 Aug 4:rs.3.rs-51964 [doi]
  • Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. medRxiv [Preprint]. 2020 Sep 17 [doi]

CASTRO QUISMONDO, Nerea

  • Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region. Thromb Res. 2021 May 8;203:93-100 [doi]

GIL MANSO, Rodrigo y Joaquín MARTÍNEZ LÓPEZ

  • Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133 [doi]

GÓMEZ ROJAS, Sandra; Gloria PÉREZ SEGURA, Gonzalo CARREÑO GÓMEZ-TARRAGONA, Elena VERA GUERRERO, María POZA SANTAELLA y Joaquín MARTÍNEZ LÓPEZ

  • A machine learning tool for the diagnosis of SARS-CoV-2 infection from hemogram parameters. J Cell Mol Med. 2023 Nov;27(22):3423-3430 [doi]

GUTIÉRREZ LÓPEZ DE OCÁRIZ, Xabier; Nerea CASTRO QUISMONDO, Elena VERA GUERRERO, Mario RODRÍGUEZ RODRÍGUEZ, Rossa AYALA DÍAZ y  Joaquín MARTÍNEZ LÓPEZ

  • Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19). Int J Lab Hematol. 2020 Dec;42(6):e280-e282 [doi]

JIMÉNEZ UBIETO, Ana 

  • Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. Hemasphere. 2021 Feb 10;5(3):e538 [doi]

LEIVAS, Alejandra; Laura SÁNCHEZ VEGA, Joaquín MARTÍNEZ LÓPEZ y Mª Liz PACIELLO

  • Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. Biomedicines. 2022 Mar 9;10(3):630 [doi]

MARTÍNEZ LÓPEZ, Joaquín

  • Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. Int J Infect Dis. 2022 Apr;117:56-64 [doi]
  • Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset. medRxiv [Preprint]. 2020 Aug 31 [doi]
  • Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033-3040 [doi]
  • Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study. medRxiv [Preprint]. 2020 Sep 30 [doi]
  • Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study. Int J Infect Dis. 2021 Feb 26:S1201-9712(21)00185-5 [doi]
  • COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant. Cancers (Basel). 2024 Jan 16;16(2):379 [doi]
  • Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study. Int J Infect Dis. 2021 Apr;105:319-325 [doi]
  • IL-6-based mortality risk model for hospitalized `patients with COVID-19. J Allergy Clin Immunol. 2020;146(4):799-807.e9 [doi]
  • Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133 [doi]
  • Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021 Dec;35(12):3585-8 [doi]
  • Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J Med Virol. 2021;93(2):831-842 [doi]

MARTÍNEZ LÓPEZ, Joaquín; R. ALONSO, J. M. SÁNCHEZ PINA, I. ZAMANILLO, N. LÓPEZ MUÑOZ, Rodrigo ÍÑIGUEZ, C. CUÉLLAR, M. CALBACHO, Mª Liz PACIELLO y Rosa AYALA

  •  Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021 Dec 10;11(12):198 [doi]

MARTÍNEZ LÓPEZ, Joaquín; Rodrigo GIL MANSO, Andrés ARROYO BAREA y María CALBACHO

  • COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study. Cancers (Basel). 2023 Feb 27;15(5):1497 [doi]

MARTÍNEZ LÓPEZ, Joaquín y Juan José LAHUERTA

  • Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality. medRxiv [Preprint]. 2020 Jun 30 [doi]
  • Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020 Oct 19;10(10):103 [doi]

MIRÁS, Fátima

  • Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol. 2020 Dec 18;9(1):37 [doi]
  • COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood. 2021 Jul 23:blood.2021011841 [doi]
  • COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 Sep;34(9):2354-2363 [doi]
  • COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021 Dec;35(12):3444-54 [doi]
  • The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. Am J Hematol. 2023 Dec;98(12):1856-1868 [doi]
  • Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience. Blood. 2020 Jul 20;blood.2020006965 [doi]
  • Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. J Hematol Oncol. 2022 Aug 26;15(1):116 [doi]

PACIELLO CORONEL, María Liz

  • A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021 Sep 2:152740 [doi]

PACIELLO CORONEL, María Liz y Carolina VILLEGAS

  • Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv [Preprint]. 2020 Sep 29 [doi]

RODRÍGUEZ, Mario y Nerea QUISMONDO

  • Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region. Thromb Res. 2021 Jul;203:93-100 [doi]

RODRÍGUEZ RODRÍGUEZ, Mario; Nerea CASTRO QUISMONDO,  Denos ZAFRA TORRES, Daniel GIL ALOS, Rosa AYALA y Joaquín MARTÍNEZ LÓPEZ

  • Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol. 2021 Jan 27 [doi]

SÁNCHEZ PINA, José María; Mario RODRÍGUEZ RODRÍGUEZ, Nerea CASTRO QUISMONDO, Rodrigo GIL MANSO, Rafael COLMENARES, Daniel GIL ALOS, María Liz PACIELLO, Denis ZAFRA, Cristina GARCÍA SÁNCHEZ, Carolina VILLEGAS, Clara CUÉLLAR, Gonzalo CARREÑO, Irene ZAMANILLO, María POZA, Rodrigo ÍÑIGUEZ, Xabier GUTIÉRREZ, Rafael ALONSO, Antonia RODRÍGUEZ, Rosa AYALA, Joaquín MARTÍNEZ LÓPEZ y María CALBACHO

  • Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597-607 [doi]

VILLEGAS DA ROS, Carolina

  • Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial. Vox Sang. 2024 Jan;119(1):27-33 [doi]
  • Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma. Vox Sang. 2023 Apr;118(4):296-300 [doi]

VILLEGAS DA ROS, Carolina; María POZA, Denis ZAFRA, Cristina GARCÍA, Elena VERA, Marta HIDALGO, Nieves LÓPEZ, Clara CUÉLLAR, Irene ZAMANILLO, Rodrigo ÍÑIGUEZ y Joaquín MARTÍNEZ LÓPEZ

  • IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. Ann Hematol. 2020;99(12):2953-2956 [doi]